Subject(s)
Cyclosporine/therapeutic use , Scleroderma, Systemic/drug therapy , Antigens, CD/blood , Antigens, Differentiation, Myelomonocytic/biosynthesis , Biopsy , Cell Adhesion , Cell Adhesion Molecules/biosynthesis , Cyclosporine/blood , E-Selectin , Enzyme-Linked Immunosorbent Assay , Female , Humans , Intercellular Adhesion Molecule-1/biosynthesis , Intercellular Adhesion Molecule-1/blood , Male , Middle Aged , Platelet Endothelial Cell Adhesion Molecule-1 , Scleroderma, Systemic/immunology , Scleroderma, Systemic/physiopathology , Skin/immunology , Skin/pathologyABSTRACT
A case of flagellate dermatitis after administration of bleomycin is reported in a patient with Hodgkin's disease. Histopathological and immunohistochemical analysis revealed a drug-induced skin toxic reaction rather than a lymphomatous infiltrate. Pigmentary changes observed after the early erythematous eruption were due to a postinflammatory effect.
Subject(s)
Bleomycin/adverse effects , Drug Eruptions/etiology , Adult , Drug Eruptions/immunology , Drug Eruptions/pathology , Female , Hodgkin Disease/drug therapy , Humans , Immunohistochemistry , Lymphocytes/immunology , Lymphocytes/pathology , Skin/immunology , Skin/pathologyABSTRACT
The paper reports a study of 34 sweat gland tumours, 3 of which were malignant. In line with recent publications on the topic, no immunophenotype is identified which could differentiate between pathologies of an eccrine as opposed to apocrine origin. With regard to the possibility of distinguishing malignant from benign tumours, the paper reconfirms the importance of CEA which is the only immunomarker common to all the malignant forms examined.
Subject(s)
Sweat Gland Neoplasms/pathology , Biomarkers, Tumor/analysis , Humans , ImmunohistochemistrySubject(s)
Bleomycin/adverse effects , Pigmentation Disorders/chemically induced , Adult , Female , Humans , ImmunohistochemistryABSTRACT
The case of a woman with systemic lupus erythematosus with unusual clinical, cutaneous and biologic features and lupus anticoagulant is presented. According to the literature this association is not fortuitous: a new syndrome characterized by the presence of a subgroup of antiphospholipid antibodies has been recognized. The cutaneous symptoms of this syndrome include: leg ulcers, livedo reticularis, widespread cutaneous necrosis and distal cutaneous ischemia. In our patient a nearly complete picture of the clinical and biologic features of this syndrome, including a characteristic retinal vein thrombosis is present.
Subject(s)
Autoimmune Diseases/pathology , Blood Coagulation Factors/immunology , Lupus Erythematosus, Systemic/pathology , Phospholipids/immunology , Blood Coagulation Disorders/etiology , Female , Humans , Leg Ulcer/etiology , Lupus Coagulation Inhibitor , Lupus Erythematosus, Systemic/immunology , Middle Aged , Retinal Vein Occlusion/etiology , SyndromeABSTRACT
A selected group of 60 patients who had been resistant to previous systemic antibiotic therapy was treated with low-dose isotretinoin (0.5 mg/kg/day in two doses) for 12 to 20 weeks. The results confirmed the efficacy of the drug on pustular, nodular and cystic acne even with low-dose treatment. In only one case was it necessary to suspend the treatment because of an increase in serum cholesterol and triglycerides. The authors therefore advise the use of low dosage and that treatment should be restricted to cases of severe acne.
